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ABSTRACT
Objective: The general objective of the study was to 
determine incidence of nevirapine toxicity in pregnant 
HIV infected women commenced on nevirapine-based 
regimen in the current pregnancy with CD4 counts up to 
3350 cells/mm  at the University Teaching Hospital, 
Lusaka, Zambia.
Design:  Longitudinal observational study with 2 arms
Group 1 (low CD4 count arm): HIV infected pregnant 
3women with CD4 counts less than 250 cells/mm  
commenced on nevirapine based regimen in pregnancy.
Group 2 (higher CD4 count arm): HIV infected pregnant 
3women with CD4 counts between 250 and 350 cells/mm  
commenced on nevirapine based regimen in pregnancy.
Main outcome:  Nevirapine toxicity (eithercutaneous 
and/or Hepatotoxicity)
Measures:
Rash- at least grade 2 rash with or without mucous 
membrane involvement.
Hepatic toxicity – at least grade 2 rise in aspartate 
aminotransferaseor alanine amino transferase
The grading of toxicity was as per WHO toxicity 
estimates (2006 WHO ART guidelines)
Results: The incidence of nevirapine toxicity (at least 
grade 2 rash with or without mucous membrane 
involvement and/or at least grade 2 rise in Aspartate 
AminoTransferase) was found to be 0% in women with 
3CD4 counts below 250cells/mm ; it was 13.5% (p=0.005) 
3in women with CD4 counts between 250 to 350cell/mm . 
Conclusions: Though the study was powered to detect 
a15% difference, the results of the study show that 
3women with CD4 counts of 250 to 350cells/mm  are at 
substantial risk of nevirapine toxicity when commenced 
on nevirapine based HAART regimen in pregnancy. 
INTRODUCTION
The use of Highly Active Antiretroviral Therapy 
(HAART) to prevent mother-to-child HIV transmission 
1,2(PMTCT) has demonstrated to be effective . This has 
been shown to be true also in developing countries even in 
3,4the face of breastfeeding .
Data on safety ofnevirapine in pregnancy has given rise to 
concern. Risk of toxicity has been shown to increase with 
3CD4 counts greater than 250cells/mm especially during 
5,6,7pregnancy . 
The US Food and Drug Administration (FDA) as well as 
the World Health Organization advises use of nevirapine 
based regimen in women with CD4 counts greater than 
8,9250 with caution . 
Nevirapine has been widely used in pregnancy both as 
single-dose therapy during labour and as part of short-
term and long-term highly active antiretroviral therapy. It 
is an effective and well tolerated non-nucleoside reverse 
transcriptase inhibitor (NNRTI) that is widely available to 
10,11prevent HIV infection in resource-poor populations .
In developing countries, choice of highly active 
antiretroviral drugs in pregnancy for therapy or for 
PMTCT remains a challenge. Efavirenz is a non 
nucleoside reverse transcriptase inhibitor that has been 
associated with neural tube defects when used in the first 
trimester. Niverapine based regimens have well 
documented cutaneous and hepatic toxicities when used 
in women with high CD4 counts. Nevirapine based 
regimen is inexpensive compared to both efavirenz and 
12protease inhibitor based regimens . Protease inhibitor 
(PI) based regimens form the back-bone of second line 
therapy and are therefore not recommended as first line 
regimen.
The Zambian MOH 2007 ART protocol guidelines (as 
well as WHO 2006 ART guidelines in resource poor 
settings) recommend initiating HAART for all HIV-1 
infected pregnant women with CD4 counts less than 
3350cells/mm . Nevirapine based regimen is the first line 
therapy for pregnant women with CD4 counts less than 
3250cells/mm . For women with CD4 counts between 250 
3and 350cells/mm , either nevirapine with frequent checks 
on liver function tests or efavirenz commenced after the 
st 9,131  trimester is recommended . 
The study determined the incidence of nevirapine toxicity 
in HIV-1 infected women commenced on nevirapine 
based regimen (zidovudine/lamivudine/nevirapine or 
stavudine/lamivudine/nevirapine) in the current 
3pregnancy with CD4 counts  up to 350 cells/mm  at the 
University Teaching Hospital, Lusaka, Zambia. It 
compared the incidence of nevirapine toxicity (cutaneous 
and hepatic toxicity) in women with CD4 counts below 
3250cells/mm  to that of women with CD4 counts between 
3250 to 350cells/mm .The studyalso documented the 
prevalence of hepatitis B co-infection in the study 
population as this is an important confounder.
METHODS
Study design: Longitudinal observational study with 2 
arms
Group 1 (low CD4 count arm): HIV infected pregnant 
3women with CD4 counts less than 250 cells/mm  
commenced on nevirapine based regimen in pregnancy.
Group 2 (higher CD4 count arm): HIV infected pregnant 
3women with CD4 counts between 250 and 350 cells/mm  
commenced on nevirapine based regimen in pregnancy.
Study duration: The study took about 11 months from 
inception
§Training study assistants-1 week
§Baseline data collection -8 months 
§Additional follow up time- 2 months
§Data analysis -1 month
Target population: All pregnant HIV infected women 
presenting to the University Teaching Hospital.
Study population: HIV infected pregnant women with 
3CD4 counts of up to 350cells/mm  commenced on 




vPregnant women with documented HIV-
positive status with CD4 counts less than or 
3 equal to 350 cells/mm commenced on 
nevirapine based regimen in current pregnancy 
vMore than 18 years and able to give informed 
consent
vWillingness to attend antenatal and postnatal 
care at UTH
Exclusion criteria
vPatients who were less than 18 years old or 
unable to give informed consent
vPatients who had been on cumulative 7 days or 
more of HAART
Study site: The study was undertaken at the University 
Teaching Hospital (UTH) Department of Obstetrics and 
Gynaecology in the Adult Infectious Disease Center 
(AIDC).Description of the study site: UTH is the largest 
as well as highest referral hospital in Zambia. Although 
primarily a referral center, UTH also provides care to self-
referred patients. It therefore has a wide spectrum of 
patients in terms of social-economic status and 
educational background.
Antenatal patients are seen in the UTH antenatal care 
clinic. After passing through the clerk's desk, patients 
receive different counseling sessions (conducted by 
midwives) before they are seen by the doctors. After the 
counseling sessions, opt out HIV testing is offered as part 
of the routine antenatal package. 
Women who tested positive as well as those who already 
had a documented HIV positive status were routinely 
examined to asses clinical stage of the disease and bloods  
taken for CD4 counts and other baseline investigations ( 
FBC, LFTs, Creatinine, RPR, hepatitis B).The patients 
were then referred to the UTH ART-antenatal care clinic 
at the Adult Infectious Disease Centre (AIDC).  
The study followed up women with CD4 counts less than 
3or equal to 350cells/mm who were commenced on 
nevirapine-based antiretroviral therapy for about 12 to 14 
weeks in order to evaluate their risk of nevirapine toxicity.
Sampling: Convenience sampling was used to enroll 146 
patients into the study. All HIV-infected pregnant women 
3with CD4 counts less than or equal to 350 cells/mm  
commenced on nevirapine based antiretroviral therapy 
seen during the study period where enrolled if they 
consented and they fulfilled the eligibility criteria. 
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3Women with CD4 counts less than 250 cells/mm  
commenced on nevirapine based regimen were allocated 
to group 1 arm and women with CD4 counts between 250 
3and 350 cells/mm  commenced on nevirapine based 
regimen in this pregnancy, to the group 2 arm.
Sample size calculation
1. Alternative hypothesis(one sided)  The incidence of 
nevirapine toxicity in HIV infected pregnant women 
who start HAART with CD4 counts between 250 and 
3 350cells/mm is higher than that of women who start 
3with CD4 counts < 250cells/mm .
2. P1 = from the literature, the incidenceof nevirapine 
toxicity in HIV infected pregnant women who start 
3 HAART with CD4 counts less than 250cells/mm is 
about1%.
3. P2 = from the literature, the incidenceof nevirapine 
toxicity in HIV-1 infected pregnant women who start 
HAART with CD4 counts  greater  than 
3250cells/mm is about 16%.
4. Alpha (one sided) = 0.05.
5. At 80% power; Beta = 1 – 0.80 = 0.20.
To detect a 15% difference in the incidence of nevirapine 
toxicity in the two arms, the required sample size was 71 
participants in each arm i.e. a total of 142 participants. 




The aim of the study was to  evaluatethe incidence of 
nevirapine toxicity in pregnant HIV-infected women 
commenced on nevirapine based regimen in the current 
pregnancy with CD4 counts less than or equal to 350 
3cells/mm  at the University Teaching Hospital, Lusaka, 
Zambia. It also aimed to compare the incidence of 
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On cotrimoxazole 136 (82%)
Not on cotrimoxazole 12 (8%)









Not done 13 (9%)
1. Proportion with grade 2 or more 
elevation in  AST/ALT i.e hepatic 
toxicity
CD4 count < 250 (n=77) 0
CD4 count250-350 (n=74) 6 (8%)
2. Proportion with grade 2 or more 
Nevirapine rash
CD4 count < 250 (n=75) 0
CD4 count250-350 (n=78) 6 (7%)
Incidence of Nevirapine toxicity (either 1 and/or 2) 13.55 p=0.005
nevirapine toxicity in women with CD4 counts less than 
3250 cells/mm  to that of women with CD4 counts of 250 
3to 350 cells/mm  as well as to evaluate the prevalence of 
hepatitis B co-infection in the study population.
The incidence of hepatic toxicity was 8%.That of 
cutaneous toxicity was about 7%. The combined 
incidence was 13.5%. The prevalence of hepatitis B co 
infection was 6%.
The findings in this study may be used in accessing the 
safety of nevirapine-based regimen in HIV positive 
pregnant women. As Ministry of Health rolls out the 
PMTCT program, more pregnant women are likely to 
commence HAART. More women with CD4 counts less 
3than 350cells/mm  will be exposed to nevirapine based 
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highly active antiretroviral therapy regimen as this is the 
recommended first line regimen.
Social demographic data: The age distribution of women 
in the study ranged from 18 to 43 years with an average of   
30.8 years.Fifty six percent (56%) had only up to 
secondary school education while 1% had no formal 
education. Thirty four (34%) of women were in formal 
employment and 22% where self employed. The low 
educational levels and the low employment levels 
contribute to the low income levels with about 33% of 
women coming from households with less than five 
hundred thousand kwacha total income per month.
Eighty nine percent (89%) of the women were married. 
This figure represents women whose partners are either 
already infected or are at very high risk of being infected. 
The huge number of married women reflects the need for 
PMTCT programs to rigorously incorporate other aspects 
of ART care such as partner notification. While antenatal 
care is an opportunity for client entry into other services 
such as primary health care, family planning, screening 
for cervical cancer etc, it is also an opportunity for entry of 
these women`s  husbands and children into ART care and 
ART-related services such as counseling and social 
support.
Fifty six percent (56%) of women were seen at the AIDC 
clinic by reason of being referred to the University 
Teaching Hospital for complicated care while 37% where 
fee paying patients in search of better care.
The mean gravidity was 3.1 with a maximum of 9 
pregnancies while the mean parity was 1.8 with a 
maximum of 8. The average number of children was 1.5. 
The progressive decrease from gravidity, parity to the 
number of children alive may be explained by the 
relatively higher incidence of pregnancy loses 
(miscarriages and still births) and pediatric deaths 
associated with the HIV infection.
The average gestation at enrollment was about 29 weeks, 
with 4 women enrolling at 41 weeks. Being referred may 
be a contributing factor to late enrollment as 56% of the 
women were referred from local clinics for complicated 
care. However, pregnant women and their partners need 
to be sensitized regarding the benefits of starting ART 
sooner in order to maximize outcome for both the mother 
and the baby.
Seventy seven (52%) women had CD4 counts less than 
3250 cells/mm  while seventy one (48%) women had CD4 
3counts between 250 and 350 cells/mm  at enrollment. 
There was poor correlation between the WHO clinical 
stage and the CD4 count in the 2 cohorts as 87% of women 
enrolled had WHO clinical stage 1 disease. Eighty two 
percent (82%) of women were commenced on 
AZT/3TC/NVP. The 27 patients (18%) commenced on 
D4T/3TC/NVP had hemoglobin less than 10g/dl when 
starting HAART. Ninety two percent (92%) of patients 
took cotrimoxazole prophylaxis as per the 2007 Ministry 
of Health, Zambia ART guidelines. Four (4) of the 6 
patients who did not take cotrimoxazol had reported prior 
allergy to the drug.
Prevalence of Hepatitis B co-infection: 8 (6%) of 142 
patients had hepatitis B co-infection. These were 
clinically stable patients with normal baseline aspartate 
alanine transferase before commencing HAART. 2 of the 
8 patients with hepatitis B co-infection had deranged liver 
function tests grade 1 and grade 2 respectively after 
commencing nevirapine based HAART regimen.
Incidence of hepatic toxicity (deranged aspartate 
aminotransferase levels): 2 (3%) of 77 patients with CD4 
3count less than 250cells/mm  had deranged aspartate 
aminotransferase. Both patients had grade 1 elevation of 
the enzyme. 
9 (12%) of 74 patients with CD4 counts between 250 to 
3350cells/mm  had altered aspartate aminotransferase. 3 of 
the nine patients had grade 1 elevation in ALT while 6 
(8%) patients had  grade 2 or more elevations in ALT.
Incidence of nevirapine rash. No patient with CD4 count 
less than 250cells/mm3 developed rash after being 
commenced on nevirapine based HAART regimen.
7 (9%) of the 71 patients with CD4 counts of 250 to 350 
had generalized maculopapular rash after being 
commenced on Nevirapine based regimen. 1 Patient had 
grade 1 rash. She was managed conservatively and 
continued on the same regimen. The other 6 (7%) had 
either grade 2 or 3 rash. None of the patients developed 
grade 4 rash and none were admitted. Nevirapine was 
promptly discontinued if rash is grade 2 or more. Steroids 
and antihistamines were given and all patients recovered 
well.
Incidence of Nevirapine toxicity (combined hepatic and 
cutaneous toxicity). The incidence of nevirapine 
toxicity (defined as either 1and/or 2):
1. Rash- at least grade 2 rash with or without mucous 
membrane involvement.
2. Hepatic toxicity – at least grade 2 rise in Aspartate 
AminoTransferaseor Alanine Amino Transferase
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Nevirapine toxicity in the CD4 count arm less than 250 
was 0%.
3In the CD4 count arm 250 to 350 cells/mm ; 6 of 74 
patients had grade 2 or more elevation in ALT and 6 of 71 
patients had grade 2 or more maculopapular rash. 2 of 
these patients had both elevation in ALT and rash. 
Therefore the incidence of nevirapine toxicity is 13.5% 
(p= 0.005) in this study population.
ACKNOWLEDGEMENT
I am deeply indebted to the patients who took part in this 
study, my supervisors Dr.BellingtonVwalika and 
Dr.NamwingaChintu, my ICRS (International Clinical 
Research Scholars) Fogarty scholarship supervisor Dr. 
Benjamin Chi, my clinical supervisor at the Adult 
Infectious Disease Centre (AIDC) Dr. Elizabeth Stringer, 
the University Teaching Hospital department of 
Obstetrics and Gynaecology as well as the entire CIDRZ 
research team for their unwavering support to see to the 
successful completion of this study. I also remain grateful 
to Ms Elizabeth Sitali, the AIDC clinic co-coordinator for 
her meticulous organization of the AIDC clinic which 
allowed for collection of data with relative ease.  
REFERENCES
1. United States Public Health Services Task Force 
recommendations for use of antiretroviral drugs in 
pregnant HIV- 1 infected women for maternal health 
and interventions to reduce perinatal HIV -1 
transmission in the United States. Rockville, MD, US 
Department of Health and Human Services, 17 
November, 2005.
2. Centers for Disease Control and Prevention. Public 
Service task force recommendations for use of 
antiretroviral drugs in pregnant women infected with 
HIV-1 for maternal health and for reducing perinatal 
hiv-1 transmission in the United States. Morbidity 
and Mortality Weekly Report,  1998, 47 
(http://aidsinfo.nih.gov/contentFiles/perinatalGL01
301998041.pdf,acessed19 June 2006).
3. Read j, Cahn P, Losso M, Pinto J, et al. A prospective 
cohort study of HIV-1 infected pregnant women and 
their infants in Latin America and the Caribbean: the 
NICHID international Site Development initiative 
thperinatal study.12  Conference on retroviruses and 
opportunistic infections. Boston, MA, USA. 22-25 
February 2005 (abstract 790). 
4. Palombi L, Marazzi MC, Voetberg A, Magid NA. 
Treatment acceleration programm and the experience 
of the DREAM program in prevention of Mother to 
Child Transmission of HIV.AIDS 2007 July;21suppl 
4:S65-71.
5. Dieterich D, Stern J, Robinson P, Hall D, Carlier H. 
Analysis of four clinical trials to assess the risk of 
hepatotoxicity with nevirapine: correlation with 
CD4+levels, hepatitis B and C seropositivity and 
baseline liver function tests. 1st International AIDS 
Society (IAS) Conference on HIV Pathogenesis and 
Treatment. Buenos Aires, Argentina, July 2001 
[Abstract 44].
6. Hitti J, Frenkel L, Huang S et al. PACTG 1022 Study 
Team. Maternal toxicity with continuous nevirapine 
in pregnancy: results from PACTG 1022. J Acquir 
Immune DeficSyndr 2004; 36: 772-776 .
7. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral 
–associated toxicity among HIV-seropositive 
pregnant women in Mozambique receiving 
Nevirapine-based regimens. JAIDS. April 2007 
[Abstract 44].
8. FDA advisory on nevirapine. AIDS Treat News. 
2005;409:7.
9. World Health Organization. Antiretroviral Drugs for 
Treating Pregnant Women and preventing HIV 
infection in infants in resource-limited settings; 
Towards Universal Access. Geneva; 2006.
10. Office of AIDS Research Advisory Council 
(OARAC), US Department of Health and Human 
Services. Guidelines for the use of antiretroviral 
agents in HIV-1-infected adults and adolescents. 
O c t o b e r  1 0 ,  2 0 0 6 .  A v a i l a b l e  a t :  
http://aidsinfo.nih.gov/ContentFiles/AdultandAdole
scentGL.pdf.
11. Marazzi MC, Germano P, Liotta G, et al. Safety of 
nevirapine-containing antiretroviral triple therapy 
regimens to prevent vertical transmission in an 
African cohort of HIV-1-infected pregnant women. 
HIV Med. 2006; 7:338-344.
12. Sabbatani S, Manfredi R, Biagetti C, et al. 
Antiretroviral therapy in the real world. Population-
based pharmacoeconomic analysis of administration 
of anti-HIV regimens to 990 patients. Clin Drug 
Invest. 2005;25:527-535.
13. Zambia National AIDS Council. Zambia National 
Protocol Guidelines: Integrated Prevention of 
Mother-to-Child Transmission of HIV/AIDS. 
Lusaka, Zambia: Printech Press;2008.
Medical Journal of Zambia, Vol. 39, No. 1 (2012)
15
